Factor IXa inhibitors

US10351558B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Dongfang Meng · Morganville, US
• Hong Li · Edison, US
• Meng Yang · San Diego, US
• Manuel de Lera Ruiz · Perkasie, US
• Sunita V. Dewnani · Secaucus, US
• Tianying Jian · Westfield, US
• Dann Parker · Cranford, US
• Ting Zhang · Princeton Junction, US
• Louis-Charles Campeau · Morristown, US
• Harold B. Wood · Westfield, US
• Jiayi Xu · Marlboro, US
• Richard Berger · Princeton, US
• Jane Yang Wu · Marlboro, US
• Robert K. Orr · Brooks Road, US
• Shawn P. Walsh · Bound Brook, US
• Bart Harper · New York, US

Key dates

• Filing date: Feb 12, 2016
• Grant date: Jul 16, 2019
• Expiry date: Feb 12, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.